leadf
logo-loader
viewOsprey Medical Ltd

Osprey Medical signs strategic sales agency agreement for new US region

Osprey’s proprietary technologies reduce the amount of contrast (dye) injected into patients during heart catheterisation procedures without compromising X-ray image quality for the physician.

Osprey Medical Ltd - Osprey Medical signs strategic sales agency agreement for new US region
Osprey has a dual-pronged sales approach across the US.

Osprey Medical Inc (ASX:OSP) has signed an independent sales agency (ISA) agreement with BioCore Inc., a sales group which specialises in selling cardiac surgery, electrophysiology and cath lab products.

Under the agreement, BioCore’s sales representatives will be strategically deployed across eight new states in the US in regions which are currently outside of Osprey’s existing direct sales force coverage.

ISA agreements are a part of Osprey’s cost-efficient sales expansion strategy with additional distributor agreements in the pipeline.

“Excited to partner with BioCore”

Osprey Medical CEO Mike McCormick said: “We are excited to partner with BioCore as part of our US expansion strategy.

“BioCore has over 20 years of experience selling heart-related technologies and has a strong presence in many hospitals in the North-eastern US.

“While we have a strong presence and continue to grow sales in the regions where our direct sales force operates, our partnership with BioCore will help strengthen our market presence in the north-eastern states in which we currently do not have a presence.

“It can be a costly process to enter new areas, especially during COVID-19 and the introduction of the ISA model will enable us to expand across the US in the most cost-effective and sustainable way.

“I look forward to adding more ISAs in other regions as we continue to expand while managing our cash burn closely.”

Increasing geographic coverage

The addition of the ISAs forms part of Osprey’s broader vision to increase its geographic coverage whilst at the same time focus on maintaining a leaner business model following COVID-19.

The strategy provides Osprey with a dual-pronged sales approach across the US, via both distributors and direct sales reps and the agreement has been structured to leverage the key advantages of both the distributor and direct sales strategy.

Osprey’s direct sales representatives will continue to focus on the regions in which they operate, however they will also work closely with the ISAs to help convert potential customers in new regions.

Under the agreement, Osprey will ship to and invoice hospitals in the ISA’s area and pay commissions to the ISA based on total revenues.

The agreement is for a 2-year term with escalating quarterly sales targets. 

Osprey is in active discussions with a number of ISAs at this stage and hopes to continue to expand its geographic coverage in the near-term.

Quick facts: Osprey Medical Ltd

Price: 0.017 AUD

ASX:OSP
Market: ASX
Market Cap: $86.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Golden Rim Resources kicks off 15,000 metre auger drilling program at Kada...

Golden Rim Resources Ltd's (ASX:GMR) Craig Mackay caught up with Proactive's Andrew Scott soon after announcing they've started an extensive fieldwork program comprising 15,000 metres of power auger drilling utilising two rigs at the Kada gold project in Guinea. It will primarily focus on a...

2 hours, 16 minutes ago

2 min read